RSV-F eiwit (Native, RSV)

RSV-F

Native

< 1.0 EU per μg of the protein as determined by the LAL method

≥ 90 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-MALS.

1. Immobilized Anti-Fusion glycoprotein F0 Antibody, Human IgG1 (Site Ø) (Nirsevimab) at 2 μg/mL (100μL/well) can bind Recombinant RSVB Prefusion glycoprotein F/ RSV-preF Protein (Cat: 40999-VNAS), the EC50 is 4-12 ng/mL. 2. Immobilized Anti-Fusion glycoprotein F0 Antibody, Human IgG1 (site II) (Palivizumab) at 2 μg/mL (100μL/well) can bind Recombinant RSVB Prefusion glycoprotein F/ RSV-preF Protein (Cat: 40999-VNAS), the EC50 is 4-12 ng/mL. 3. Immobilized Anti-Fusion glycoprotein F0 Antibody, Human IgG1 (AM14) at 2 μg/mL (100μL/well) can bind Recombinant RSVB Prefusion glycoprotein F/ RSV-preF Protein (Cat: 40999-VNAS), the EC50 is 4-12 ng/mL. 4.Nirsevimab-derived anti-RSV-preF antibody, Human IgG1 captured on Protein A chip, can bind Human respiratory syncytial virus (RSVB) Prefusion glycoprotein F/ RSV-preF Protein (Cat. No. 40999-VNAS) with an affinity constant of 0.720 nM as determined in an SPR assay (Biacore 8K) (Routinely tested) .

It migrates as an approximately 58.2 kDa band in SDS-PAGE under reducing conditions. The molecular weight of this protein is around 160.8 kDa verified by SEC-MALS.

RSV